Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: CliniMACs Clear all
Completed Phase 2 Interventional

Hematopoietic Stem Cell Transplant for Fanconi Anemia

NCT01071239
View directory record Official record
Conditions
Fanconi Anemia
Interventions
CliniMACs device, Busulfan, Fludarabine, Cyclophosphamide, ATG
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 10, 2026, 5:40 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

NCT00539500
View directory record Official record
Conditions
Neuroblastoma
Interventions
Carboplatin, Etoposide, Melphalan, Stem Cell Infusion, ClinicMACS
Drug · Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 10, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

NCT03524235
View directory record Official record
Conditions
Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Interventions
Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion, Bendamustine, Fludarabine, Rituximab
Radiation · Procedure · Biological + 1 more
Lead sponsor
Noah Merin
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 10, 2026, 5:40 AM EDT
Recruiting Phase 1 Interventional

Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation

NCT04804891
View directory record Official record
Conditions
Intestinal Transplantation
Interventions
Cell Therapy
Biological
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 10, 2026, 5:40 AM EDT
Recruiting Phase 1Phase 2 Interventional

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

NCT05480449
View directory record Official record
Conditions
B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma
Interventions
Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
0 Years to 29 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 10, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

Stem Cell Transplantation for Patients With Multiple Myeloma

NCT01526096
View directory record Official record
Conditions
Myeloma
Interventions
G-CSF, Plerixafor, Apheresis, Melphalan, Stem cell re-infusion, Basiliximab, CliniMACS CD25 microbeads and cell sorter
Drug · Procedure · Device
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 10, 2026, 5:40 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV

NCT04364178
View directory record Official record
Conditions
Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus
Interventions
Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, EBV Specific T-Lymphocytes
Biological
Lead sponsor
Jessie L. Alexander, MD
Other
Eligibility
1 Month to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 10, 2026, 5:40 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

NCT07052370
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Thymoglobulin, Cyclophosphamide, Fludarabine, Thiotepa, Melphalan, Mesna, Filgrastim, Blinatumomab, CliniMACS
Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 10, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients

NCT02395822
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
IL-15
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 10, 2026, 5:40 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease

NCT06986382
View directory record Official record
Conditions
Crohn Disease
Interventions
CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin, ATG, Clofarabine, Melphalan, Total Body Irradiation, Rituximab
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 30 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 10, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

NCT00987480
View directory record Official record
Conditions
Aplastic Anemia, Leukemia, Myelodysplastic Syndrome
Interventions
Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine., CliniMACS device
Drug · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 10, 2026, 5:40 AM EDT
Terminated Phase 1 Interventional

A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies

NCT00569179
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphoid, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic
Interventions
CliniMACS CD34 Reagent System
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Sep 10, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

NCT00566696
View directory record Official record
Conditions
Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia (JMML), Hemoglobinuria, Paroxysmal Nocturnal (PNH), Hodgkin Lymphoma, Lymphoma, Non-Hodgkin (NHL), Myelodysplastic Syndrome (MDS)
Interventions
CliniMACS, Stem cell transplantation, Fludarabine, Thioplex®, L-phenylalanine mustard, Mycophenolate mofetil, Rituxan™, Alemtuzumab, Cyclophosphamide, Anti-thymocyte globulin (Rabbit), G-CSF, Muromonab
Device · Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Sep 10, 2026, 5:40 AM EDT
Recruiting Not applicable Interventional

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

NCT05794880
View directory record Official record
Conditions
Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplasia, Acute Lymphoblastic Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia With Crisis of Blast Cells, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma, Burkitt Leukemia, Lymphoma After Relapse, Other Malignant Hematologic Diseases in Remission
Interventions
Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
0 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 10, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML

NCT03050216
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
ALT-803
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 10, 2026, 5:40 AM EDT
Recruiting Phase 2 Interventional

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

NCT05800210
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
Interventions
Miltenyi CliniMACS Prodigy ® system
Device
Lead sponsor
University of Florida
Other
Eligibility
6 Months to 39 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 10, 2026, 5:40 AM EDT
Recruiting Phase 1 Interventional

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

NCT06879340
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Interventions
DuoCAR20.19.22-D95, Fludarabine (Conditional therapy), Cyclophosphamide (Conditional therapy)
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 10, 2026, 5:40 AM EDT
Enrolling by invitation Phase 2 Interventional

KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children

NCT02646839
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
CliniMacs TCR alpha-beta-Biotin system
Device
Lead sponsor
Michael Pulsipher
Other
Eligibility
Up to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Oakland, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 10, 2026, 5:40 AM EDT
Recruiting Not applicable Interventional

Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection

NCT01189786
View directory record Official record
Conditions
Stem Cell Transplant, Allogeneic
Interventions
CliniMACS CD34 Reagent system
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 10, 2026, 5:40 AM EDT
Terminated Phase 2 Interventional Results available

Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

NCT02199041
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Cyclophosphamide, Thiotepa, Fludarabine, Melphalan, Mesna, G-CSF, Mycophenolate mofetil, Tacrolimus, Methylprednisolone, Total lymphoid irradiation, Lymphocyte infusions, CliniMACS
Drug · Biological · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 10, 2026, 5:40 AM EDT
Recruiting Not applicable Interventional

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure

NCT06569082
View directory record Official record
Conditions
Graft Failure, Poor Graft Function
Interventions
CD34+ Selected Donor Cell Boost, Blood Stem Cell Infusion
Device · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 10, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device

NCT01071226
View directory record Official record
Conditions
Malignant Diseases (ie, Leukemia, MDS, Lymphoma), Non-malignant Diseases (ie, Bone Marrow Failure Syndromes)
Interventions
CliniMACS (CD+3, CD+19 depletion), CliniMACS (CD 34+ positive selection), HSCT
Device · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 22 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 24, 2021 · Synced Sep 10, 2026, 5:40 AM EDT
Completed Phase 2 Interventional

Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies

NCT00143559
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
Interventions
Systematic chemotherapy and antibodies, Allogeneic stem cell transplantation, Miltenyi CliniMACS
Drug · Procedure · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Sep 10, 2026, 5:40 AM EDT
Completed Not applicable Interventional Results available

Natural Killer (NK) Cell Transplantation for AML

NCT00187096
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2, Natural Killer Cell Infusion, CliniMACS System
Drug · Procedure · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Sep 10, 2026, 5:40 AM EDT